Yohei Ozawa1, Toru Nakano2,3, Yusuke Taniyama2, Tadashi Sakurai2, Yu Onodera2, Kurodo Kamiya2,4, Makoto Hikage2, Chiaki Sato2, Kai Takaya2, Takuro Konno2, Michiaki Unno2, Takashi Kamei2. 1. Department of Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan. ozawa.youhei@opal.plala.or.jp. 2. Department of Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan. 3. Division of Gastroenterological and Hepatobiliarypancreatic Surgery, Tohoku Medical and Pharmaceutical University, Sendai, Japan. 4. Department of Gastrointestinal Surgery, Iwate Prefectural Central Hospital, Morioka, Japan.
Abstract
BACKGROUND: The impact of sarcopenia on digestive cancer is widely known. Muscle mass, defined as the psoas muscle index (PMI), is an important parameter of sarcopenia. However, the relationship between esophageal cancer and PMI has not been fully investigated, especially in patients receiving neoadjuvant therapy. METHODS: To elucidate the influence of the PMI on patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy, the progression of sarcopenia defined by the PMI, the relationship between pretherapeutic/preoperative sarcopenia and patient characteristics, and patient survival were retrospectively investigated in 82 patients with esophageal squamous cell carcinoma who underwent neoadjuvant therapy. RESULTS: The PMI decreased by more than 20 mm2/m2 between the pretherapeutic and preoperative periods in 75.6% of the patients. Pretherapeutic sarcopenia (low PMI) correlated with the pathological therapeutic response, postoperative recurrence, and pretherapeutic body mass index. Neoadjuvant chemoradiotherapy was associated with the progression of sarcopenia. The pretherapeutic sarcopenia group (low PMI) had worse disease-free survival (DFS) than the non-sarcopenia group. Furthermore, pretherapeutic sarcopenia (low PMI) was an independent prognostic risk factor of DFS according to univariate and multivariate analyses. CONCLUSIONS: The PMI may decrease during neoadjuvant therapy, especially during neoadjuvant chemoradiotherapy. Pretherapeutic sarcopenic (low PMI) patients should be followed-up more carefully postoperatively because higher risks of recurrence and poorer rates of disease-free survival are associated with these patients.
BACKGROUND: The impact of sarcopenia on digestive cancer is widely known. Muscle mass, defined as the psoas muscle index (PMI), is an important parameter of sarcopenia. However, the relationship between esophageal cancer and PMI has not been fully investigated, especially in patients receiving neoadjuvant therapy. METHODS: To elucidate the influence of the PMI on patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy, the progression of sarcopenia defined by the PMI, the relationship between pretherapeutic/preoperative sarcopenia and patient characteristics, and patient survival were retrospectively investigated in 82 patients with esophageal squamous cell carcinoma who underwent neoadjuvant therapy. RESULTS: The PMI decreased by more than 20 mm2/m2 between the pretherapeutic and preoperative periods in 75.6% of the patients. Pretherapeutic sarcopenia (low PMI) correlated with the pathological therapeutic response, postoperative recurrence, and pretherapeutic body mass index. Neoadjuvant chemoradiotherapy was associated with the progression of sarcopenia. The pretherapeutic sarcopenia group (low PMI) had worse disease-free survival (DFS) than the non-sarcopenia group. Furthermore, pretherapeutic sarcopenia (low PMI) was an independent prognostic risk factor of DFS according to univariate and multivariate analyses. CONCLUSIONS: The PMI may decrease during neoadjuvant therapy, especially during neoadjuvant chemoradiotherapy. Pretherapeutic sarcopenic (low PMI) patients should be followed-up more carefully postoperatively because higher risks of recurrence and poorer rates of disease-free survival are associated with these patients.
Authors: J Ignacio de Ulíbarri; A González-Madroño; N G P de Villar; P González; B González; A Mancha; F Rodríguez; G Fernández Journal: Nutr Hosp Date: 2005 Jan-Feb Impact factor: 1.057
Authors: Kostan W Reisinger; Jeroen L A van Vugt; Juul J W Tegels; Claire Snijders; Karel W E Hulsewé; Anton G M Hoofwijk; Jan H Stoot; Maarten F Von Meyenfeldt; Geerard L Beets; Joep P M Derikx; Martijn Poeze Journal: Ann Surg Date: 2015-02 Impact factor: 12.969
Authors: Val Gebski; Bryan Burmeister; B Mark Smithers; Kerwyn Foo; John Zalcberg; John Simes Journal: Lancet Oncol Date: 2007-03 Impact factor: 41.316
Authors: Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni Journal: Age Ageing Date: 2010-04-13 Impact factor: 10.668
Authors: K Kumagai; I Rouvelas; J A Tsai; D Mariosa; F Klevebro; M Lindblad; W Ye; L Lundell; M Nilsson Journal: Br J Surg Date: 2014-02-03 Impact factor: 6.939
Authors: S Matsuda; H Takeuchi; K Fukuda; R Nakamura; T Takahashi; N Wada; H Kawakubo; Y Saikawa; T Omori; Y Kitagawa Journal: Dis Esophagus Date: 2013-08-27 Impact factor: 3.429
Authors: Ioannis G Kaklamanos; Gail R Walker; Kristian Ferry; Dido Franceschi; Alan S Livingstone Journal: Ann Surg Oncol Date: 2003-08 Impact factor: 5.344
Authors: Josh McGovern; Ross D Dolan; Paul G Horgan; Barry J Laird; Donald C McMillan Journal: J Cachexia Sarcopenia Muscle Date: 2021-10-18 Impact factor: 12.910